Skip to content

Study · Animal study (in vivo) · cynomolgus monkey, dog and rat · 1990

12 results

Oral activity of the growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in rats, dogs and monkeys.

Walker RF, Codd EE, Barone FC, Nelson AH, Goodwin T, Campbell SA

Life sciences1 Jan 1990Cited by 37 (Europe PMC)

PMID2117689 (opens in a new tab)DOI10.1016/0024-3205(90)90563-7 (opens in a new tab)PepBankPUB-02117689
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In rats, enterally administered GHRP‑6 showed GH-releasing activity.

    In plain wordsIn rats, GHRP‑6 given through the digestive tract released GH.

    Peptide
    GHRP-6
    Outcome
    IncreaseEnteral GH activity
    Study

    ratn: not reported in source

    rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · oral gavageAs given in this study (rat).

    Source sentences

    Summary
    Enteral activity of GHRP-6 was observed in all 3 species tested.
    1 context sentence
    Summary · context
    The purpose of this study was to evaluate the growth hormone (GH) releasing activity of orally administered His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6, SK&F 110679) in rats, dogs and monkeys. Rats were administered GHRP-6 orally by gavage or parenterally through femoral artery catheters.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In dogs, enterally administered GHRP‑6 showed GH-releasing activity.

    In plain wordsIn dogs, GHRP‑6 given through the digestive tract released GH.

    Peptide
    GHRP-6
    Outcome
    IncreaseEnteral GH activity
    Study

    dogn: not reported in source

    dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intragastric and intraduodenalAs given in this study (dog).

    Source sentences

    Summary
    Enteral activity of GHRP-6 was observed in all 3 species tested.
    1 context sentence
    Summary · context
    The purpose of this study was to evaluate the growth hormone (GH) releasing activity of orally administered His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6, SK&F 110679) in rats, dogs and monkeys.
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In monkeys, intragastric GHRP‑6 showed GH-releasing activity.

    In plain wordsIn monkeys, GHRP‑6 given into the stomach released GH.

    Peptide
    GHRP-6
    Outcome
    IncreaseEnteral GH activity
    Study

    cynomolgus monkeyn: not reported in source

    cynomolgus monkeys
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intragastricAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Enteral activity of GHRP-6 was observed in all 3 species tested.
    1 context sentence
    Summary · context
    Cynomolgus monkeys were administered GHRP-6 i.g., and blood was collected from abdominal aorta for estimation of changes in plasma GH.
  4. 04AnimalAnimal study (in vivo)Activity measurement

    In rats, enteral GHRP‑6 had a GH-releasing ED50 of 4 mg/kg.

    In plain wordsIn rats, the study measured the dose of enteral GHRP‑6 needed for half-maximal GH release.

    Peptide
    GHRP-6
    Outcome
    Not applicableEnteral ED50
    Study

    ratn: not reported in source

    rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · oral gavageAs given in this study (rat).

    Measurements

    ED50
    4 mg/kg
    enteral rats

    Source sentences

    Summary
    In rats, ED50's for enteral and parenteral administration of GHRP-6 were 4 mg/kg and 28 micrograms/kg, respectively.
    1 context sentence
    Summary · context
    Rats were administered GHRP-6 orally by gavage or parenterally through femoral artery catheters.
  5. 05AnimalAnimal study (in vivo)Activity measurement

    In rats, parenteral GHRP‑6 had a GH-releasing ED50 of 28 micrograms/kg.

    In plain wordsIn rats, the study measured the dose of injected GHRP‑6 needed for half-maximal GH release.

    Peptide
    GHRP-6
    Outcome
    Not applicableParenteral ED50
    Study

    ratn: not reported in source

    rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · femoral artery catheterAs given in this study (rat).

    Measurements

    ED50
    28 micrograms/kg
    parenteral rats

    Source sentences

    Summary
    In rats, ED50's for enteral and parenteral administration of GHRP-6 were 4 mg/kg and 28 micrograms/kg, respectively.
    1 context sentence
    Summary · context
    Rats were administered GHRP-6 orally by gavage or parenterally through femoral artery catheters.
  6. 06AnimalAnimal study (in vivo)Activity measurement

    In rats, enteral GHRP‑6 had 0.7% of parenteral bioactivity.

    In plain wordsIn rats, enteral GHRP‑6 was less active than parenteral GHRP‑6.

    Peptide
    GHRP-6
    Outcome
    DecreaseRelative enteral bioactivity
    Study

    ratn: not reported in source

    rats
    Comparator
    Parenteral GHRP-6
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · oral gavageAs given in this study (rat).

    Measurements

    Relative bioactivity
    0.7%
    enteral versus parenteral rats

    Source sentences

    Summary
    Thus in rats, enterally administered GHRP-6 was 0.7% as bioactive as the parenterally administered peptide.
  7. 07AnimalAnimal study (in vivo)Activity measurement

    In dogs, intragastric GHRP‑6 had an approximate ED50 of 15 mg/kg.

    In plain wordsIn dogs, the study measured the dose of stomach-administered GHRP‑6 needed for half-maximal GH release.

    Peptide
    GHRP-6
    Outcome
    Not applicableIntragastric ED50
    Study

    dogn: not reported in source

    dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intragastricAs given in this study (dog).

    Measurements

    ED50
    ≈ 15 mg/kg
    intragastric dogs

    Source sentences

    Summary
    In dogs GHRP-6 was slightly less potent than in rats, with ED50's for i.g. and i.v. administration approximately 15 mg/kg and 125 micrograms/kg, respectively.
  8. 08AnimalAnimal study (in vivo)Activity measurement

    In dogs, intravenous GHRP‑6 had an approximate ED50 of 125 micrograms/kg.

    In plain wordsIn dogs, the study measured the dose of intravenous GHRP‑6 needed for half-maximal GH release.

    Peptide
    GHRP-6
    Outcome
    Not applicableIntravenous ED50
    Study

    dogn: not reported in source

    dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (dog).

    Measurements

    ED50
    ≈ 125 micrograms/kg
    intravenous dogs

    Source sentences

    Summary
    In dogs GHRP-6 was slightly less potent than in rats, with ED50's for i.g. and i.v. administration approximately 15 mg/kg and 125 micrograms/kg, respectively.
  9. 09AnimalAnimal study (in vivo)Activity measurement

    In dogs, enteral GHRP‑6 had 0.8% of parenteral potency.

    In plain wordsIn dogs, enteral GHRP‑6 was less potent than parenteral GHRP‑6.

    Peptide
    GHRP-6
    Outcome
    DecreaseRelative enteral potency
    Study

    dogn: not reported in source

    dogs
    Comparator
    Parenteral GHRP-6
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intragastricAs given in this study (dog).

    Measurements

    Relative potency
    0.8%
    enteral versus parenteral dogs

    Source sentences

    Summary
    However, enteral potency of GHRP-6 in dogs was 0.8% of parenteral potency, and thus, comparable to that in rats.
  10. 10AnimalAnimal study (in vivo)Activity measurement

    In dogs, plasma GH comparisons suggested greater GHRP‑6 activity through the intraduodenal than intragastric route.

    In plain wordsIn dogs, GHRP‑6 appeared more active in the duodenum than in the stomach.

    Peptide
    GHRP-6
    Outcome
    IncreaseActivity by enteral route
    Study

    dogn: not reported in source

    dogs
    Comparator
    Intragastric GHRP-6
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intraduodenalAs given in this study (dog).

    Source sentences

    Summary
    Additionally, comparison of plasma GH levels following i.g. vs i.d. administration in dogs suggested greater activity by the i.d. route.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In monkeys, intragastric GHRP‑6 increased plasma GH at doses as low as 0.3 mg/kg.

    In plain wordsIn monkeys, low doses of GHRP‑6 given into the stomach increased blood GH.

    Peptide
    GHRP-6
    Outcome
    IncreaseLow-dose intragastric GH response
    Study

    cynomolgus monkeyn: not reported in source

    cynomolgus monkeys
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.3 mg/kg · intragastricAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Monkeys were the species most sensitive to enterally administered GHRP-6, with plasma GH increased in those receiving i.g. doses as low as 0.3 mg/kg and an ED50 of 0.75 mg/kg compared to 4 and 15 mg/kg in rats and dogs, respectively.
    1 context sentence
    Summary · context
    Cynomolgus monkeys were administered GHRP-6 i.g., and blood was collected from abdominal aorta for estimation of changes in plasma GH.
  12. 12AnimalAnimal study (in vivo)Activity measurement

    In monkeys, intragastric GHRP‑6 had an ED50 of 0.75 mg/kg, compared with 4 in rats and 15 in dogs.

    In plain wordsIn monkeys, intragastric GHRP‑6 required a lower dose for half-maximal GH release than in rats or dogs.

    Peptide
    GHRP-6
    Outcome
    Not applicableIntragastric ED50
    Study

    cynomolgus monkeyn: not reported in source

    cynomolgus monkeys
    Comparator
    Rats and dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intragastricAs given in this study (cynomolgus monkey).

    Measurements

    ED50
    0.75 mg/kg
    intragastric monkeys

    Source sentences

    Summary
    Monkeys were the species most sensitive to enterally administered GHRP-6, with plasma GH increased in those receiving i.g. doses as low as 0.3 mg/kg and an ED50 of 0.75 mg/kg compared to 4 and 15 mg/kg in rats and dogs, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:59 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.